ClinicalTrials.gg
RecruitingNCT05979493Updated Sep 11, 2026

QL Block in Laparoscopic Myomectomy

A Phase 4 interventional study of Bupivacain and Saline in Postoperative Pain and Fibroid Uterus, sponsored by Joseph Findley MD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Joseph Findley MD · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study aims to determine the efficacy of a quadratus lumborum (QL) block in decreasing postoperative pain in patients undergoing myomectomy for uterine fibroids. A QL block is a temporary anesthetic injection in the quadratus lumborum muscle, a muscle in the lower back, that has been previously shown to significantly reduce postoperative pain levels in patients undergoing abdominal and pelvic surgery. Because of its demonstrated effects, the QL block is becoming a standard of anesthesia and surgical care. Since participants will be undergoing a myomectomy procedure, the investigators believe that participants may qualify to participate in this study. The investigators will be comparing patients who receive the QL block (in addition to standard anesthesia and postoperative pain care) with patients who do not receive the QL block (in addition to standard care). The participants will be randomly assigned to one of the two groups and may or may not actually receive the block.

02

Conditions studied

  • Postoperative Pain
  • Fibroid Uterus

Keywords

  • QL Block
  • Myomectomy
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 80 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with Joseph Findley MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of uterine fibroids requiring surgical excision with preservation of the uterus
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Provision of signed and dated form

Exclusion criteria

Exclusion Criteria:

  • Pre-existing diagnoses of anxiety or depression
  • Pre-existing coagulopathies
  • Pre-existing neuropathic or chronic pelvic pain
  • Chronic opioid use
  • Illiteracy due to inability to read and understand plain questionnaire
  • Non-English speaking
  • >38
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    QL Block with Bupivacaine

    Participants will get a QL block using 30cc Bupivacaine bilaterally in quadratus lumborum muscle (60cc total).

    Drug: Bupivacain

  • Sham comparator
    Control

    Participants will get a sham injection of 30cc saline bilaterally in quadratus lumborum muscle (60cc total).

    Drug: Saline

Interventions

  • 30cc IM injection in each quadratus lumborum muscle (60cc total).

  • DrugSaline

    30cc IM injection in each quadratus lumborum muscle (60cc total).

06

What researchers measure

Primary outcomes

  1. Time in minutes from first analgesic request as measured by medical chart review

    Time frame: Up to 24 hours

  2. Total number of doses of rescue analgesics given as measured by medical chart review

    Time frame: Up to 24 hours

Secondary outcomes

  1. Pain as measured by visual analog scale (VAS)

    VAS is a pain scale from 0-10 with 0 being no pain and 10 being the worst pain ever.

    Time frame: Up to 48 hours after discharge from hospital.

  2. Patient satisfaction with perioperative pain management measured on a scale of 1-10

    Pain management scale with 1 being very disappointed in pain management with 10 being highly satisfied with pain managment.

    Time frame: Up to 48 hours after discharge from hospital.

Other outcomes

  1. Pain as measured by Richmond Agitation Sedation Scale (RASS)

    RASS is measured from -5 to +4 with -5 being no response to voice or physical stimulation and +4 being overtly combative, violent, immediate danger to staff

    Time frame: Up to 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2028, 46 months after the start.

Of 531 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 46 months is above that.

Counting every sponsor, half of 541 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 7, 2023
StartActual
Aug 24, 2024
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 3, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05979493
Lead sponsor
Joseph Findley MD
Responsible party
Joseph Findley MD (University Hospitals Department of Reproductive Endocrinology and Infertility, University Hospitals Cleveland Medical Center) — Sponsor-investigator
First posted
Aug 7, 2023
Start date
Aug 24, 2024
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Catherine P Haering, BA
Contact
cph43@case.edu
3392011531
Joseph Findley, MD
principal investigator · University Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion